Fortaz, Zavicefta(ceftazidime)
Avycaz, Ceftazidime, Fortaz, Tazicef, Zavicefta (ceftazidime) is a small molecule pharmaceutical. Ceftazidime was first approved as Fortaz on 1985-07-19. It is used to treat acinetobacter infections, bacterial infections, bacterial meningitis, bacterial pneumonia, and bacterial skin diseases amongst others in the USA. It has been approved in Europe to treat bacterial pneumonia, gram-negative bacterial infections, pneumonia, soft tissue infections, and urinary tract infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Tazicef (discontinued: Ceftazidime, Ceptaz, Fortaz, Pentacef, Tazicef, Tazidime)
CombinationsAvycaz
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ceftazidime
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CEFTAZIDIME IN DEXTROSE CONTAINER | B. Braun Medical | N-050823 DISCN | 2011-06-13 | 2 products, RLD |
| CEPTAZ | GSK | N-050646 DISCN | 1990-09-27 | 4 products |
| FORTAZ | PAI Pharma | N-050578 DISCN | 1985-07-19 | 4 products, RLD |
Hide discontinued
Avibactam sodium
+
Ceftazidime
Ceftazidime sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FORTAZ IN PLASTIC CONTAINER | PAI Pharma | N-050634 DISCN | 1989-04-28 | 3 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| avycaz | New Drug Application | 2025-04-25 |
| ceftazidime | ANDA | 2024-01-03 |
| fortamet | New Drug Application | 2010-03-15 |
| fortaz | New Drug Application | 2017-07-28 |
| tazicef | ANDA | 2024-07-04 |
Indications
FDA
EMA
Show 10 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
AVIBACTAM SODIUM / CEFTAZIDIME, AVYCAZ, ALLERGAN | |||
| 2025-12-20 | NPP | ||
| 2025-02-25 | GAIN | ||
| 2020-02-25 | NCE | ||
Clinical
Clinical Trials
145 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | 1 | — | 1 |
| Pseudomonas infections | D011552 | EFO_0001076 | A41.52 | — | — | — | 1 | — | 1 |
| Pseudomonas aeruginosa | D011550 | NCBITaxon_287 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial infections | D001424 | — | A49 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ceftazidime |
| INN | ceftazidime |
| Description | Ceftazidime is a third-generation cephalosporin antibiotic bearing pyridinium-1-ylmethyl and {[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It has a role as an antibacterial drug, an EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor and a drug allergen. It is a cephalosporin and an oxime O-ether. It is a conjugate acid of a ceftazidime(1-). |
| Classification | Small molecule |
| Drug class | cephalosporins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 72558-82-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL44354 |
| ChEBI ID | 3508 |
| PubChem CID | 5481173 |
| DrugBank | DB00438 |
| UNII ID | DZR1ENT301 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Avycaz – Allergan
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Avycaz – Warner Chilcott
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Zavicefta – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Ceftazidime
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 42,347 documents
View more details
Safety
Black-box Warning
Black-box warning for: Fortamet
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11,544 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use